查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1438147

至 2030 年磺胺類藥物市場預測：按類型、配方、給藥途徑、應用、最終用戶和地區進行的全球分析

Sulphonamides Market Forecasts to 2030 - Global Analysis By Type (Sulfamethoxazole, Sulfadiazine, Sulfacetamide, Sulfasalazine, Sulfadoxine and Other Types), Formulation, Route of Administration, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球磺胺類藥物市場規模為 1.1521 億美元，預計 2030 年將達到 1.8621 億美元，預測期內複合年成長率為 7.1%。

磺胺類藥物是一種合成抗生素，常用於治療細菌感染疾病。它作為細菌葉酸合成的競爭性抑制劑，抑制必要的代謝過程並抑制細菌生長。全身磺胺類藥物類藥物可口服或腸胃外給藥，用於治療多種感染疾病，局部製劑可解決局部問題。磺胺類藥物的多功能性在人類醫學和獸醫學中都有應用。

根據 NCBI 統計，美國每年報告超過 1400 萬例蜂窩組織炎病例，使其成為最常見的細菌性皮膚感染疾病之一。蜂窩組織炎每年導致 65 萬人住院治療，門診醫療費用約 37 億美元。

感染疾病增加

全球感染疾病的增加增加了對磺醯胺類磺胺類藥物的磺胺類藥物，因為它們可以有效治療細菌感染疾病。由於迫切需要有效治療方法各種細菌性疾病，製藥業預計將增加這些藥物的使用。這一趨勢在人口不斷成長和醫療基礎設施發達的地區尤為明顯，加強了磺胺類藥物在更廣泛範圍內應對感染疾病持續挑戰的作用。

人們越來越擔心副作用

患者和醫療專業人員都對皮疹和過敏反應等副作用表示擔憂，阻礙了該藥物的廣泛普及。患者和醫療保健專業人員對潛在的不利事件表示擔憂，從而影響了該藥物的整體普及。副作用的風險可能會降低患者的依從性，並使醫生不願意開立磺胺類藥物。這種擔憂可能會導致人們對替代抗生素和治療方案的偏好發生轉變，從而阻礙市場成長。

人口成長和醫療基礎設施發展

隨著人口的成長，細菌感染疾病的盛行率增加，增加了對有效治療方法的需求。特別是在發展中地區，醫療設施的改善改善了磺胺類藥物的取得並增加了使用量。加強醫療基礎設施將有助於更好的診斷和治療，促進磺胺類藥物在各種感染疾病管理中的應用。人口成長和醫療能力提高的動態協同效應使磺胺類藥物成為滿足快速發展的社會日益成長的醫療需求的重要組成部分。

活動頻譜有限

在需要頻譜覆蓋的情況下，替代抗生素是首選。尋求綜合治療的醫生可以選擇活性更廣泛的抗生素。由於其作用範圍有限，磺胺類藥物胺類抗生素可能被排除在治療方法之外，從而限制了其使用和市場佔有率。這一限制阻礙了磺胺類藥物的多功能性，並且在更廣泛的抗菌頻譜被認為對於有效的治療性介入至關重要的情況下提出了挑戰。

COVID-19 的影響

COVID-19 的爆發擾亂了供應鏈並導致抗菌藥物的需求波動，從而影響了磺胺類藥物市場。醫療重點轉向控制大流行，影響了日常護理。製造和通路的中斷以及經濟的不確定性進一步影響了磺胺類藥物市場。然而，由於某些磺胺類藥物對於治療細菌感染疾病至關重要，我們預期市場將保持需求，同時適應更廣泛的全球醫療保健領域持續存在的挑戰。

錠劑市場預計將在預測期內成為最大的市場

錠劑市場預計將出現良好的成長。磺胺類藥物錠劑抗生素的一種，在治療細菌感染疾病方面發揮重要作用。這些錠劑含有磺基化合物，透過抑制葉酸合成來抑制細菌生長。磺胺類藥物錠劑通常用於治療尿道感染、呼吸道感染疾病和其他細菌性疾病，它提供了一種有針對性的治療方法。正在進行研究以改進配方並克服局限性，以確保磺胺類藥物錠劑對多種細菌感染疾病保持有效。

預計抗生素領域在預測期內複合年成長率最高

預計抗菌產業在預測期內將經歷最高的複合年成長率。作為抗菌劑，磺胺類藥物在對抗細菌感染疾病方面發揮重要作用。磺胺類藥物因其抑菌特性而被廣泛使用，可抑制細菌葉酸合成並抑制 DNA 和 RNA 的產生。這使其能夠有效對抗多種細菌病原體。磺胺類藥物的抗菌作用延伸至感染疾病、泌尿系統和感染疾病。磺胺類藥物作為抗菌療法仍然具有至關重要的作用，並為世界對抗細菌性疾病的武器庫做出了重大貢獻。

佔比最高的地區

由於北美地區醫療基礎設施發達、研發實力雄厚、感染疾病率高，預計在預測期內將佔最高佔有率。該地區擁有完善的製藥業，促進了磺胺類藥物製劑的創新。此外，由於醫藥產品的進步和積極主動的感染疾病管理方法，北美仍然是一個強勁的市場。

複合年成長率最高的地區：

由於醫療基礎設施不斷增加、感染疾病流行和人口快速成長等因素，亞太地區磺胺類藥物市場正在經歷顯著成長。該地區製藥業的擴張和政府對抗感染疾病的努力正在推動市場需求。亞太國家擴大採用磺胺類藥物來治療細菌感染疾病，重點是改善醫療保健的可近性。此外，持續的研發活動也促進了市場的活力，使亞太地區成為磺胺類藥物市場的主要參與者。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球磺胺類藥物市場：依類型

  • 磺胺甲噁唑
  • 磺胺嘧啶
  • 磺胺乙醯胺
  • 柳氮磺吡啶
  • 磺胺多辛
  • 其他

第6章全球磺胺類藥物市場：依配方分類

  • 錠劑
  • 液體
  • 粉末
  • 其他

第7章全球磺胺類藥物市場：依給藥途徑分類

  • 口服
  • 胃腸外的
  • 局部的

第8章全球磺胺類藥物市場：依應用分類

  • 抗菌的
  • 抗真菌劑
  • 抗瘧疾藥
  • 利尿劑
  • 抗病毒藥
  • 其他

第9章全球磺胺類藥物市場：依最終用戶分類

  • 製藥
  • 獸醫
  • 農業
  • 化妝品
  • 食品與飲品
  • 其他

第10章全球磺胺類藥物市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • Viatris Inc
  • Pfizer Inc
  • AA Pharma Inc
  • GlaxoSmithKline PLC
  • Azurity Pharmaceuticals
  • Teva Pharmaceutical Industries Limited
  • Valeo Pharma
  • Novartis Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd
  • Akorn Operating Company LLC
  • Sanofi SA
  • Roche Holding AG
  • Merck & Co.
  • Bayer AG
  • Johnson & Johnson
  • Abbott Laboratories
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
Product Code: SMRC25116

According to Stratistics MRC, the Global Sulphonamides Market is accounted for $115.21 million in 2023 and is expected to reach $186.21 million by 2030 growing at a CAGR of 7.1% during the forecast period. Sulphonamides are a class of synthetic antimicrobial drugs commonly used to treat bacterial infections. Acting as competitive inhibitors of folic acid synthesis in bacteria, they hinder essential metabolic processes, suppressing bacterial growth. Systemic sulphonamides are administered orally or parenterally for widespread infections, while topical formulations address localized issues. Their versatility extends to applications in both human and veterinary medicine.

According to NCBI, over 14 million cases of cellulitis are reported each year in the U.S., making it one of the most frequent bacterial skin infections. It is responsible for 650,000 hospital admissions per year and ambulatory care expenses of about USD 3.7 billion.

Market Dynamics:

Driver:

Increasing prevalence of infectious diseases

The mounting incidence of infectious diseases globally enhances the need for sulphonamides since these antimicrobial medicines successfully treat bacterial infections. Given the pressing need for efficient therapies against a variety of bacterial diseases, the pharmaceutical industry expects to see an increase in the use of these medications. This trend is particularly pronounced in regions with expanding populations and improving healthcare infrastructures, reinforcing sulphonamides' role in addressing the persistent challenge of infectious diseases on a broader scale.

Restraint:

Rising concerns about side effects

Concerns regarding possible side effects like rashes and allergic reactions are voiced by both patients and medical professionals, which hinders the drug's general uptake. Patients and healthcare professionals express apprehensions about potential adverse events, impacting the drug's overall adoption. The perceived risk of side effects can lead to a decline in patient compliance and reluctance among physicians to prescribe sulphonamides. This apprehension may divert preference towards alternative antibiotics or treatment options, hindering the market growth.

Opportunity:

Growing population and healthcare infrastructure

With a growing populace, the incidence of bacterial infections rises, fostering increased demand for effective treatments. Improved healthcare facilities, especially in developing regions, enhance access to sulphonamides, amplifying their usage. The strengthened healthcare infrastructure facilitates better diagnosis and treatment, promoting the adoption of sulphonamides in managing various infectious diseases. This dynamic synergy between population growth and enhanced healthcare capabilities positions sulphonamides as essential components in addressing the escalating healthcare needs of burgeoning societies.

Threat:

Limited spectrum of activity

In scenarios requiring broad-spectrum coverage, alternative antibiotics are the most favoured. Physicians, aiming for comprehensive treatments, may opt for antibiotics with a broader range of activity. The constrained scope of sulphonamides may result in their exclusion from treatment regimens, limiting their application and market share. This limitation hinders the versatility of sulphonamides, posing a challenge in situations where a more expansive antibacterial spectrum is deemed crucial for effective therapeutic interventions.

Covid-19 Impact

The covid-19 pandemic has influenced the sulphonamides market by disrupting supply chains, causing fluctuations in demand for antimicrobial agents. Healthcare priorities shifted towards managing the pandemic, impacting routine treatments. Disruptions in manufacturing and distribution channels, along with economic uncertainties, further affected the sulphonamides market. However, the essential nature of some sulphonamides in treating bacterial infections likely sustained demand, with the market adapting to ongoing challenges in the broader context of the global healthcare landscape.

The tablets segment is expected to be the largest during the forecast period

The tablets segment is estimated to have a lucrative growth. Sulphonamides tablets, a class of antimicrobial drugs, play a crucial role in treating bacterial infections. These tablets contain sulfa-based compounds that inhibit bacterial growth by interfering with folate synthesis. Commonly prescribed for urinary tract infections, respiratory tract infections, and other bacterial ailments, sulphonamide tablets offer a targeted therapeutic approach. Ongoing research aims to enhance formulations and overcome limitations, ensuring sulphonamide tablets continue to be effective and relevant in addressing a range of bacterial infections.

The antibacterial segment is expected to have the highest CAGR during the forecast period

The antibacterial segment is anticipated to witness the highest CAGR growth during the forecast period. Sulphonamides, as antibacterial agents, play a crucial role in combating bacterial infections. Widely utilized for their bacteriostatic properties, sulphonamides inhibit bacterial folate synthesis, impeding DNA and RNA production. This makes them effective against a range of bacterial pathogens. Their antibacterial application extends to respiratory, urinary, and skin infections. Sulphonamides continue to be pivotal in antibacterial therapeutics, contributing significantly to the global arsenal against bacterial diseases.

Region with largest share:

North America is projected to have the highest share over the forecast period, owing to its advanced healthcare infrastructure, robust research and development initiatives, and a high prevalence of infectious diseases. The region's well-established pharmaceutical sector fosters innovation in sulphonamide formulations. Further, North America remains a prominent market, with pharmaceutical advancements and a proactive approach toward infectious disease management fueling its continued prominence.

Region with highest CAGR:

The sulphonamides market in Asia Pacific is experiencing notable growth due to factors such as increasing healthcare infrastructure, rising prevalence of infectious diseases, and a burgeoning population. The region's expanding pharmaceutical industry, coupled with government initiatives to combat infections, propels market demand. With a focus on improving healthcare accessibility, countries in Asia Pacific are witnessing higher adoption of sulphonamides for treating bacterial infections. Additionally, ongoing research and development activities contribute to the market's dynamism, positioning Asia Pacific as a key player in the sulphonamides market.

Key players in the market

Some of the key players profiled in the Sulphonamides Market include Viatris Inc, Pfizer Inc, AA Pharma Inc, GlaxoSmithKline PLC, Azurity Pharmaceuticals, Teva Pharmaceutical Industries Limited, Valeo Pharma, Novartis Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Akorn Operating Company LLC, Sanofi S.A., Roche Holding AG, Merck & Co., Bayer AG, Johnson & Johnson, Abbott Laboratories, Bristol Myers Squibb Company, Eli Lilly and Company, AstraZeneca PLC and Boehringer Ingelheim International GmbH.

Key Developments:

In August 2022, Valeo Pharma Inc. and Novartis Pharmaceuticals Canada Inc., a subsidiary of Novartis AG, signed a supply and distribution agreement for SIMBRINZA in Canada. Brinzolamide is a carbonic anhydrase inhibitor and sulfonamide with a specific affinity for carbonic anhydrase II. This move ensured a broader reach of its products in the global market.

In July 2022, Azurity Pharmaceuticals Inc. received approval from the US FDA for ZONISADE (zonisamide oral suspension). Zonisamide is a sulfonamide antiepileptic drug.

Types Covered:

  • Sulfamethoxazole
  • Sulfadiazine
  • Sulfacetamide
  • Sulfasalazine
  • Sulfadoxine
  • Other Types

Formulations Covered:

  • Tablets
  • Liquid
  • Powder
  • Other Formulations

Route of Administrations Covered:

  • Oral
  • Parenteral
  • Topical

Applications Covered:

  • Antibacterial
  • Antifungal
  • Antimalarial
  • Diuretic
  • Antiviral
  • Other Applications

End Users Covered:

  • Pharmaceuticals
  • Veterinary Medicine
  • Agriculture
  • Cosmetics
  • Food & Beverage
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Sulphonamides Market, By Type

  • 5.1 Introduction
  • 5.2 Sulfamethoxazole
  • 5.3 Sulfadiazine
  • 5.4 Sulfacetamide
  • 5.5 Sulfasalazine
  • 5.6 Sulfadoxine
  • 5.7 Other Types

6 Global Sulphonamides Market, By Formulation

  • 6.1 Introduction
  • 6.2 Tablets
  • 6.3 Liquid
  • 6.4 Powder
  • 6.5 Other Formulations

7 Global Sulphonamides Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Parenteral
  • 7.4 Topical

8 Global Sulphonamides Market, By Application

  • 8.1 Introduction
  • 8.2 Antibacterial
  • 8.3 Antifungal
  • 8.4 Antimalarial
  • 8.5 Diuretic
  • 8.6 Antiviral
  • 8.7 Other Applications

9 Global Sulphonamides Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceuticals
  • 9.3 Veterinary Medicine
  • 9.4 Agriculture
  • 9.5 Cosmetics
  • 9.6 Food & Beverage
  • 9.7 Other End Users

10 Global Sulphonamides Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Viatris Inc
  • 12.2 Pfizer Inc
  • 12.3 AA Pharma Inc
  • 12.4 GlaxoSmithKline PLC
  • 12.5 Azurity Pharmaceuticals
  • 12.6 Teva Pharmaceutical Industries Limited
  • 12.7 Valeo Pharma
  • 12.8 Novartis Pharmaceuticals
  • 12.9 Sun Pharmaceutical Industries Ltd
  • 12.10 Akorn Operating Company LLC
  • 12.11 Sanofi S.A.
  • 12.12 Roche Holding AG
  • 12.13 Merck & Co.
  • 12.14 Bayer AG
  • 12.15 Johnson & Johnson
  • 12.16 Abbott Laboratories
  • 12.17 Bristol Myers Squibb Company
  • 12.18 Eli Lilly and Company
  • 12.19 AstraZeneca PLC
  • 12.20 Boehringer Ingelheim International GmbH

List of Tables

  • Table 1 Global Sulphonamides Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Sulphonamides Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Sulphonamides Market Outlook, By Sulfamethoxazole (2021-2030) ($MN)
  • Table 4 Global Sulphonamides Market Outlook, By Sulfadiazine (2021-2030) ($MN)
  • Table 5 Global Sulphonamides Market Outlook, By Sulfacetamide (2021-2030) ($MN)
  • Table 6 Global Sulphonamides Market Outlook, By Sulfasalazine (2021-2030) ($MN)
  • Table 7 Global Sulphonamides Market Outlook, By Sulfadoxine (2021-2030) ($MN)
  • Table 8 Global Sulphonamides Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 9 Global Sulphonamides Market Outlook, By Formulation (2021-2030) ($MN)
  • Table 10 Global Sulphonamides Market Outlook, By Tablets (2021-2030) ($MN)
  • Table 11 Global Sulphonamides Market Outlook, By Liquid (2021-2030) ($MN)
  • Table 12 Global Sulphonamides Market Outlook, By Powder (2021-2030) ($MN)
  • Table 13 Global Sulphonamides Market Outlook, By Other Formulations (2021-2030) ($MN)
  • Table 14 Global Sulphonamides Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 15 Global Sulphonamides Market Outlook, By Oral (2021-2030) ($MN)
  • Table 16 Global Sulphonamides Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 17 Global Sulphonamides Market Outlook, By Topical (2021-2030) ($MN)
  • Table 18 Global Sulphonamides Market Outlook, By Application (2021-2030) ($MN)
  • Table 19 Global Sulphonamides Market Outlook, By Antibacterial (2021-2030) ($MN)
  • Table 20 Global Sulphonamides Market Outlook, By Antifungal (2021-2030) ($MN)
  • Table 21 Global Sulphonamides Market Outlook, By Antimalarial (2021-2030) ($MN)
  • Table 22 Global Sulphonamides Market Outlook, By Diuretic (2021-2030) ($MN)
  • Table 23 Global Sulphonamides Market Outlook, By Antiviral (2021-2030) ($MN)
  • Table 24 Global Sulphonamides Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 25 Global Sulphonamides Market Outlook, By End User (2021-2030) ($MN)
  • Table 26 Global Sulphonamides Market Outlook, By Pharmaceuticals (2021-2030) ($MN)
  • Table 27 Global Sulphonamides Market Outlook, By Veterinary Medicine (2021-2030) ($MN)
  • Table 28 Global Sulphonamides Market Outlook, By Agriculture (2021-2030) ($MN)
  • Table 29 Global Sulphonamides Market Outlook, By Cosmetics (2021-2030) ($MN)
  • Table 30 Global Sulphonamides Market Outlook, By Food & Beverage (2021-2030) ($MN)
  • Table 31 Global Sulphonamides Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.